Compare EBF & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | EMBC |
|---|---|---|
| Founded | 1909 | 1924 |
| Country | United States | United States |
| Employees | N/A | 1850 |
| Industry | Office Equipment/Supplies/Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.9M | 524.1M |
| IPO Year | 1994 | 2021 |
| Metric | EBF | EMBC |
|---|---|---|
| Price | $21.99 | $9.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 123.1K | ★ 797.7K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | 4.50% | ★ 6.78% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | ★ 1.31 | 0.74 |
| Revenue | N/A | N/A |
| Revenue This Year | $0.11 | $1.17 |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | $16.98 | ★ $11.96 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.30 | $8.47 |
| 52 Week High | $22.36 | $15.55 |
| Indicator | EBF | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 50.39 |
| Support Level | $17.60 | $8.60 |
| Resistance Level | N/A | $9.36 |
| Average True Range (ATR) | 0.37 | 0.36 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 73.94 | 87.82 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.